NASDAQ:GILDGilead Sciences Stock Price, Forecast & News

Gilead Sciences' stock was trading at $73.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GILD stock has increased by 3.6% and is now trading at $76.32. View which stocks have been most impacted by Coronavirus.

28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 3 sell ratings, 15 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Gilead Sciences.

Gilead Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Gilead Sciences.

Gilead Sciences, Inc. (NASDAQ:GILD) posted its earnings results on Thursday, April, 30th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.57 by $0.11. The biopharmaceutical company had revenue of $5.55 billion for the quarter, compared to the consensus estimate of $5.44 billion. Gilead Sciences had a net margin of 21.84% and a return on equity of 35.44%. The company's revenue was up 5.1% compared to the same quarter last year. During the same period last year, the firm earned $1.67 EPS. View Gilead Sciences' earnings history.

Gilead Sciences announced a quarterly dividend on Thursday, April 30th. Shareholders of record on Friday, June 12th will be given a dividend of $0.68 per share on Monday, June 29th. This represents a $2.72 dividend on an annualized basis and a yield of 3.56%. The ex-dividend date of this dividend is Thursday, June 11th. View Gilead Sciences' dividend history.

28 brokerages have issued 1 year price targets for Gilead Sciences' stock. Their forecasts range from $60.00 to $97.00. On average, they expect Gilead Sciences' share price to reach $79.65 in the next year. This suggests a possible upside of 4.4% from the stock's current price. View analysts' price targets for Gilead Sciences.

Press coverage about GILD stock has been trending somewhat negative recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Gilead Sciences earned a news impact score of -1.8 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Gilead Sciences.

Gilead Sciences saw a drop in short interest in the month of June. As of June 15th, there was short interest totaling 24,140,000 shares, a drop of 7.5% from the May 31st total of 26,090,000 shares. Based on an average daily volume of 21,470,000 shares, the short-interest ratio is presently 1.1 days. Currently, 1.9% of the shares of the stock are short sold. View Gilead Sciences' Current Options Chain.

Some companies that are related to Gilead Sciences include Amgen (AMGN), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include Walt Disney (DIS), Alibaba Group (BABA), NVIDIA (NVDA), Netflix (NFLX), Intel (INTC), Micron Technology (MU), AbbVie (ABBV), Johnson & Johnson (JNJ), AT&T (T) and Tesla (tsla).

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Gilead Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Confluence Investment Management LLC (0.10%), Envestnet Asset Management Inc. (0.08%), State of Alaska Department of Revenue (0.04%), Wedge Capital Management L L P NC (0.04%), Manning & Napier Group LLC (0.04%) and DNB Asset Management AS (0.03%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John C Martin, John Francis Cogan, Olsen Per Wold and Richard James Whitley. View institutional ownership trends for Gilead Sciences.

GILD stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Robecosam AG, Fulton Bank N. A., Confluence Investment Management LLC, Municipal Employees Retirement System of Michigan, Nexus Investment Management ULC, Whittier Trust Co., and Private Asset Management Inc.. Company insiders that have sold Gilead Sciences company stock in the last year include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John Francis Cogan, and Olsen Per Wold. View insider buying and selling activity for Gilead Sciences.

GILD stock was purchased by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, State of Alaska Department of Revenue, Thomasville National Bank, DNB Asset Management AS, Manning & Napier Group LLC, Exane Derivatives, Cardinal Capital Management Inc., and Canandaigua National Corp. View insider buying and selling activity for Gilead Sciences.

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GILD stock can currently be purchased for approximately $76.32.

Gilead Sciences has a market capitalization of $95.73 billion and generates $22.45 billion in revenue each year. The biopharmaceutical company earns $5.39 billion in net income (profit) each year or $6.14 on an earnings per share basis. Gilead Sciences employs 11,800 workers across the globe.

The official website for Gilead Sciences is www.gilead.com.

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]